Range Low Price High Price Comment
30 days $3.76 $3.76 Friday, 27th May 2022 CHMA stock ended at $3.76. During the day the stock fluctuated 0% from a day low at $3.76 to a day high of $3.76.
90 days $3.76 $3.76
52 weeks $3.76 $4.93

Historical Chiasma prices

Date Open High Low Close Volume
2022-03-17 $3.76 $3.76 $3.76 $3.76 0
2022-03-16 $3.76 $3.76 $3.76 $3.76 0
2022-03-15 $3.76 $3.76 $3.76 $3.76 0
2022-03-14 $3.76 $3.76 $3.76 $3.76 0
2022-03-11 $3.76 $3.76 $3.76 $3.76 0
2022-03-10 $3.76 $3.76 $3.76 $3.76 0
2022-03-09 $3.76 $3.76 $3.76 $3.76 0
2022-03-08 $3.76 $3.76 $3.76 $3.76 0
2022-03-07 $3.76 $3.76 $3.76 $3.76 0
2022-03-04 $3.76 $3.76 $3.76 $3.76 0
2022-03-03 $3.76 $3.76 $3.76 $3.76 0
2022-03-02 $3.76 $3.76 $3.76 $3.76 0
2022-03-01 $3.76 $3.76 $3.76 $3.76 0
2022-02-28 $3.76 $3.76 $3.76 $3.76 0
2022-02-25 $3.76 $3.76 $3.76 $3.76 0
2022-02-24 $3.76 $3.76 $3.76 $3.76 0
2022-02-23 $3.76 $3.76 $3.76 $3.76 0
2022-02-22 $3.76 $3.76 $3.76 $3.76 0
2022-02-18 $3.76 $3.76 $3.76 $3.76 0
2022-02-17 $3.76 $3.76 $3.76 $3.76 0
2022-02-16 $3.76 $3.76 $3.76 $3.76 0
2022-02-15 $3.76 $3.76 $3.76 $3.76 0
2022-02-14 $3.76 $3.76 $3.76 $3.76 0
2022-02-11 $3.76 $3.76 $3.76 $3.76 0
2022-02-10 $3.76 $3.76 $3.76 $3.76 0
Click to get the best stock tips daily for free!

About Chiasma

Chiasma Chiasma, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases. Its product candidate is octreotide capsules or MYCAPSSA, which has completed Phase III clinical trial for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Newton, Massa... CHMA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT